Sensyne Health to Help Bayer Develop Cardiovascular Drugs
July 31 2019 - 4:09AM
Dow Jones News
By Carlo Martuscelli
Sensyne Health PLC (SENS.LN) said Wednesday that it will work
with Germany's Bayer AG (BAYN.XE) to help it identify new
treatments for cardiovascular disease in a contract worth 5 million
pounds ($6.1 million) over two years for the British clinical
artificial intelligence company.
Under the terms of the collaboration agreement, Bayer will use
Sensyne's technology platform to accelerate drug development.
Trusts belonging to U.K.'s National Health Service, which have a
stake in Sensyne and provide it with patient data, will be due a 4%
share of revenues generated by the collaboration, the company
said.
Shares of Sensyne at 0830 GMT were up 6.7% at 160 pence.
Write to Carlo Martuscelli at carlo.martuscelli@dowjones.com
(END) Dow Jones Newswires
July 31, 2019 04:54 ET (08:54 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Bayer Aktiengesellschaft (PK) (USOTC:BAYRY)
Historical Stock Chart
From Apr 2024 to May 2024
Bayer Aktiengesellschaft (PK) (USOTC:BAYRY)
Historical Stock Chart
From May 2023 to May 2024